Blackstone Life Sciences
Overview
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors . By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| GRIN Therapeutics, Inc. | May 2025 | Series D | Lead |
| Anagram Therapeutics Inc. | May 2026 | Early Funding | Lead |
| AvenCell | Oct 2024 | Series B | Co-investor |
| Avillion Life Sciences | May 2014 | Early Funding | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Blackstone Life Sciences based?
Blackstone Life Sciences is headquartered in Cambridge, Massachusetts, United States.
When was Blackstone Life Sciences founded?
Blackstone Life Sciences was founded in 2005.
How many portfolio companies does Blackstone Life Sciences have?
Blackstone Life Sciences has 7 portfolio companies in Caplight's dataset.
What are some companies in Blackstone Life Sciences's portfolio?
Portfolio companies visible on Caplight include GRIN Therapeutics, Inc., Anagram Therapeutics Inc., AvenCell, Avillion Life Sciences.
What was Blackstone Life Sciences's most recent investment shown here?
Blackstone Life Sciences's most recent investment in this portfolio sample was in Anagram Therapeutics Inc. in 2026.
What sectors does Blackstone Life Sciences focus on?
Blackstone Life Sciences focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Blackstone Life Sciences focus on?
Blackstone Life Sciences typically invests at the MultiStage stage.
What is Blackstone Life Sciences's AUM?
Blackstone Life Sciences's assets under management are estimated between $10.0B and $100.0B.